

International Neuropsychiatric Disease Journal

Volume 21, Issue 4, Page 18-25, 2024; Article no.INDJ.116110 ISSN: 2321-7235, NLM ID: 101632319

Negative Implications of Drug and Substance use on Mental Health

Okoye, Nelyn Akunna ^{a*}, Udeji, Rosemary Nneka ^b, Ordu, Charles Nkesi ^a, Aneke, Emeka John ^c, Offor, Chinazor Cordelia ^d and Asanya, Chinyere Ada ^e

^a Department of Health Service, Rivers State University, Nigeria.
^b Ikate Primary Health Centre, Lagos State, Nigeria.
^c University of Nigerian Teaching Hospital, Enugu State, Nigeria.
^d St. Catherine's Specialist Hospital Port Harcourt, Nigeria.
^e U.S Food and Drug Administration, Tampa Florida, USA.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/INDJ/2024/v21i4439

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/116110

Review Article

Received: 04/03/2024 Accepted: 08/05/2024 Published: 11/05/2024

ABSTRACT

Mental health refers to a person's emotional, psychological, and social well-being, which encompasses aspects such as thoughts, feelings, behaviors, and the ability to cope with life's challenges. Several factors including drug abuse have been recognized to cause mental health disorders; hence, the urgent need to globally address these factors. Drug abuse emerges as a complex public health issue, involving the misuse of legal and illegal drugs, with consequences extending beyond individual health. The relationship between mental health and drug abuse intensifies challenges, as drug misuse contributes to the development or worsening of mental health disorders. This review examined biological, psychological, and social determinants, and advocate for a standardized approach to address the complex issue of drug abuse. Various

^{*}Corresponding author: E-mail: chidimma.azike@ust.edu.ng, nelyn.okoyeagbo@gmail.com;

Akunna et al.; Int. Neuropsy. Dis. J., vol. 21, no. 4, pp. 18-25, 2024; Article no.INDJ.116110

electronic databases, such as PubMed, Scopus, Web of Science, Medline, and others, were used to access resources, in which thirty-three (33) literatures were reviewed. Results of the reviewed literatures revealed that the impact of drug abuse on mental health involves neurobiological alterations affecting neurotransmitter levels and structural changes in the brain. This does not only affect individuals, but also results in societal burdens, such as increased healthcare costs and criminal justice involvement, compounded by the stigma surrounding mental health and substance abuse. The classification of drugs into legal and illegal categories highlights the diversity of substances and emphasizes the need to understand their effects on mental well-being. Categories include legal drugs, prescription medications, socially accepted substances, and illegal drugs with varying dependency potentials. Addressing mental health disorders induced by drug abuse requires a comprehensive approach, involving strategies like Integrated Dual Diagnosis Treatment (IDDT), Medication-Assisted Treatment (MAT), Cognitive-Behavioral Therapy (CBT), Motivational Interviewing (MI), Dialectical Behavior Therapy (DBT), Peer Support, 12-Step Programs, and Recovery-Oriented Systems of Care (ROSC). These methods guarantee a care continuum that centers on the individual and emphasizes recovery, acknowledging the relationship between mental health and drug abuse disorders. Nevertheless, the review highlights a research gap in that, indepth research is needed to evaluate the effectiveness of the aforementioned interventions. Additionally, exploring innovative strategies to address challenges such as stigma, limited treatment accessibility, and the cyclical nature of addiction would enhance intervention effectiveness.

Keywords: Mental health; drug abuse; well-being; global public health; depression; anxiety; bipolar disorder.

1. INTRODUCTION

Mental health is a critical aspect of overall wellbeing that encompasses emotional, psychological, and social dimensions [1]. It plays a fundamental role in how individuals think, feel, and behave, influencing their ability to cope with stress, relate to others, and make decisions. Mental health is not just the absence of mental disorders but also the presence of positive characteristics such as resilience, self-esteem, and emotional well-being [2].

The prevalence of mental health disorders worldwide highlights the urgency of addressing this global public health challenge. Conditions like depression, anxiety, and bipolar disorder affect millions of people, impacting their daily lives, relationships, and overall quality of life [3]. Furthermore, the social stigma linked to mental health concerns frequently results in reduced reporting and obstacles to seeking assistance [3].

Drug abuse, being a pervasive and complex public health issue, possesses significant challenges globally [4]. It involves the misuse or overuse of substances, both legal and illegal, leading to adverse physical, psychological, and social consequences. This phenomenon has farreaching implications for individuals, families, and communities, necessitating a comprehensive understanding of its causes, effects, and potential interventions [4]. The misuse of substances such as opioids, stimulants, and sedatives has become a major concern, contributing to a rising number of substancerelated disorders and overdoses [5]. The consequences of drug abuse extend beyond individual health, affecting societal well-being through increased healthcare costs, crime rates, and strained social services [5].

Mental health and substance abuse are intertwined aspects of human well-being that significantly influence each other [6]. The relationship between mental health and drug abuse is complex and multifaceted, with each playing a key role in shaping the outcomes for individuals [7]. Extensive research has examined this association, demonstrating that substance misuse can profoundly affect mental health by worsening existing conditions and, in some instances, triggering the onset of new mental health disorders [8]. In recent years, the prevalence of drug abuse and its impact on mental health has gathered increased attention from researchers, healthcare professionals, and policymakers (World Health Organization, 2017) [5].

Biological, psychological, and social determinants all play a role in the initiation and maintenance of substance misuse [9]. Also, genetic predispositions, mental health disorders, and environmental influences contribute to the

complexity of drug abuse, making it necessary to adopt a standardized approach in addressing this issue [9] However, despite ongoing efforts, challenges persist in addressing drug abuse. Stigma surrounding substance misuse, limited access to treatment, and the cyclical nature of addiction contribute to high rates of relapse [10]. Furthermore, the changing availability of drugs and the appearance of new types of substances continue to be problems that policymakers and healthcare workers have to deal with [10]. However, this review article aims to provide a comprehensive examination of the interplay between mental health and drug abuse.

1.1 Literature Search Methods

In this review a comprehensive literature search was conducted. Various electronic databases, including PubMed, Scopus, Web of Science, and Medline, were queried to access relevant publications. Additionally, books and other scholarly resources were consulted to gather comprehensive information on the topic.

1.2 Search Strategy and Keywords

The search strategy employed a structured approach, incorporating keywords, controlled vocabulary terms, and Boolean operators. The search was conducted across various electronic databases, including PubMed, Scopus, Web of Science, and Medline, to ensure comprehensive material collection. In PubMed, the following search strategy was utilized: (("Mental health" [MeSH Terms] OR "Mental health" [Title/Abstract] OR "Mental disorders" [MeSH Terms] OR "Mental disorders" [Title/Abstract]) AND ("Substance-Related Disorders" [MeSH "Substance-Related Disorders" Terms] OR "Substance [Title/Abstract] OR Abuse, Intravenous" [MeSH Terms] OR "Substance Abuse, Intravenous" [Title/Abstract])) OR ("Drug [MeSH Terms] OR "Drug Abuse" Abuse" [Title/Abstract] OR "Drug Addiction" [MeSH Terms] OR "Drug Addiction" [Title/Abstract]). These elements, combined with Boolean operators such as "AND" and "OR," were strategically integrated to enhance precision and capture a broad spectrum of literature on the relationship between mental health and drug abuse

2. IMPACT OF DRUG ABUSE ON MENTAL HEALTH

The impact of drug abuse on mental health is a critical area of concern, reflecting the complex

interconnection between substance misuse and psychological well-being. Substance abuse, encompassing the misuse of legal and illegal substances, has profound consequences on mental health, affecting individuals across various demographics and presenting challenges for both healthcare providers and policymakers (Smith and Johnson, 2020).

The relationship between drug abuse and mental health is bidirectional, with each influencing and exacerbating the other. Substance misuse can contribute to the development, aggravation, or recurrence of mental health disorders, including anxiety, depression, and psychosis [11]. Additionally, individuals with pre-existing mental health conditions may be more vulnerable to the harmful effects of substance abuse, creating a complex cycle of mutual reinforcement [12]. One of the primary impacts of drug abuse on mental health is the alteration of neurobiological processes within the brain. Substance use can lead to changes in neurotransmitter levels, affecting mood, cognition, and behavior [13]. The chronic use of certain substances may also contribute to structural changes in the brain, further influencing mental health outcomes [14].

The consequences of drug abuse on mental health extend beyond the individual level to impact families, communities, and society at large. Increased rates of substance use disorders contribute to societal burdens, including healthcare costs, criminal justice involvement, and lost productivity [15]. Moreover, the stigma associated with both mental health issues and substance abuse often leads to underreporting and barriers to seeking timely and effective treatment [16].

According to Barrett et al. [17], the association between substance abuse and violent or offending conduct goes beyond community violence, including occurrences in domestic settings and institutions. The use of substances plays a substantial role in influencing the public health repercussions of the cycle of domestic violence, surpassing other contributing factors. Longman-Mills and her team investigated the link between childhood physical abuse and later instances of psychological distress and substance abuse among university students. Their study indicated that undergoing physical abuse in childhood heightens the probability of experiencing heightened psychological distress and engaging in substance abuse in adulthood [18], which would, in consequence, exacerbate their mental well-being.

3. CLASSIFICATION OF DRUGS

Nowadays, various classification systems for drugs exist, broadly dividing them into two major groups:

3.1 Legal Drugs

Legal drugs are those manufactured, produced, bought, and sold within the boundaries of the law. Examples include aspirin, cough syrups, antacids. vitamins. laxatives. and certain contraceptives. These non-prescription drugs serve various purposes such as hunger control, stimulation, and relief and are sedation. produced and marketed globally for billions of dollars. Drugs and medications dispensed by pharmacists based on prescriptions from doctors and dentists fall under the category of prescription drugs. These encompass analgesics, contraceptives, antibiotics, medicated shampoos, stimulants, sedatives, antidepressants, anesthetics, and others. However, some psychoactive prescription drugs, like amphetamines, barbiturates, and narcotics, are abused to alter states of consciousness. Socially accepted psychoactive drugs, such as alcohol, tobacco, coffee, and tea, fall into three categories: non-prescription drugs, prescription drugs, and social drugs (nicotine, caffeine, and alcohol) [14].

3.2 Illegal Drugs

Illegal drugs are those not used legally but are abused. They can be further divided based on their potential to produce high or low dependence. Substances like amphetamines, cocaine, depressants, and narcotics tend to produce high dependency, while marijuana and other hallucinogens result in low dependency. The nature of illegal drugs varies concerning their ability to induce clinical dependency. Heroin, cocaine, amphetamines, and barbiturates strongly produce dependence, while marijuana, lysergic acid diethylamide (LSD), and psilocybin create weaker dependence [14].

4. THE MECHANISM OF ACTION OF DRUGS OF ABUSE

The mechanism of action of drugs of abuse on the central nervous system (CNS) involves

complex interactions with neurotransmitter systems [14]. Various classes of drugs, including stimulants, depressants, opioids, hallucinogens, and cannabinoids, exert their effects by targeting specific receptors and neurotransmitter pathways within the CNS. Some of the drugs of abuse, and their respective mechanism of action include the following:

a) Stimulants (for example, cocaine, amphetamines)

Stimulant drugs primarily target the dopamine system. Cocaine, for instance, inhibits the reuptake of dopamine in the synapses, leading to an accumulation of dopamine and prolonged reward pathwavs sianalina in [19]. Amphetamines, on the other hand, promote the release of dopamine and other neurotransmitters, contributing to heightened arousal and euphoria [20].

b) Depressants (for example, alcohol, benzodiazepines)

Depressant drugs primarily enhance the activity of the inhibitory neurotransmitter gammaaminobutyric acid (GABA). Alcohol, for example, potentiates GABAergic signaling, leading to sedation and relaxation [14]. Benzodiazepines act on GABA-A receptors, increasing the inhibitory effects of GABA [21].

c) Opioids (for example, heroin, prescription painkillers)

Opioid drugs activate opioid receptors in the CNS, modulating pain perception and reward pathways. Heroin and prescription opioids bind to mu-opioid receptors, leading to analgesia and euphoria (Kieffer and Evans, 2009).

d) Hallucinogens (for example, LSD, psilocybin)

Hallucinogenic drugs primarily interact with serotonin receptors. Lysergic acid diethylamide (LSD), for instance, activates serotonin receptors, leading to altered perceptions and hallucinations (Nichols, 2004). Psilocybin, found in "magic mushrooms," has a similar mechanism of action.

e) Cannabinoids (for example, THC)

Cannabinoid	drugs,	like	delta-9-
tetrahydrocannabinol		(THC),	activate

cannabinoid receptors (CB1 and CB2) in the CNS. CB1 receptors are abundant in the brain and play a role in the psychoactive effects of cannabis (Pertwee, 2006).

5. DRUGS OF ABUSE AND THEIR EFFECTS ON MENTAL WELL-BEING

Categorization of drugs of abuse is based on their nature, origin, mechanism of action, and effects. Among these categories are narcotic analgesics, such as codeine and morphine, which slow down a person and induce feelings of euphoria. Medically, narcotics signify opium and opium derivatives with high addictive potential. Movina to another category, stimulants temporarily stimulate the mind and body, exciting or speeding up the central nervous system. Commonly used stimulants include nicotine and caffeine, while more potent ones like cocaine and amphetamines can lead to intoxication and ecstasy.

Depressants, also known as "downers," slow down mental functions, especially the central nervous system, heart rate, and respiration. People may use depressants for relaxation, calmness, and improved sleep. Additionally, cannabis, derived from the marijuana plant, contains various cannabinoids. Products like hashish, marijuana, and bhang fall under this category, impacting psychoactive properties.

Transitioning to commonly abused substances, ranging from legal medications to illicit drugs, they have profound effects on mental health, influencing emotional, psychological, and cognitive aspects of well-being [22,23].

Alcohol, one of the most widely consumed psychoactive substances globally, may not necessarily lead to adverse mental health effects with moderate consumption. However, excessive and chronic alcohol abuse is associated with an increased risk of depression, anxiety disorders, and cognitive impairments [24]. Opioids, including prescription painkillers and illicit drugs like heroin, can have profound effects on the central nervous system. Prolonged use may lead to symptoms of depression, anxiety, and a heightened risk of developing opioid use disorder (Volkow et al., 2018).

Abuse of stimulants, like Cocaine and Methamphetamine, can result in heightened arousal, increased energy, and euphoria. However, the misuse of stimulants is linked to

mental health issues such as paranoia, anxiety, and even psychosis [23]. Cannabis, commonly used for its psychoactive effects, is under ongoing research for its impact on mental health. Chronic use has been associated with an increased risk of anxiety disorders and may exacerbate symptoms in individuals with prehealth existina mental conditions [22]. Additionally, nicotine, primarily consumed through tobacco products, is addictive and has psychoactive effects. Smoking is often linked to mood disorders, and individuals with mental health conditions are more likely to smoke [25].

6. TREATMENT OF MENTAL HEALTH DISORDERS INDUCED BY DRUG ABUSE

The treatment of individuals with mental health disorders interconnected with drug abuse requires a comprehensive and integrated approach, essential for promoting lasting recovery and improving overall well-being. Various treatment approaches aim to address the complex relationship between mental health and substance use disorders. Integrated Dual Diagnosis Treatment (IDDT) is a widely recoanized approach that simultaneously addresses mental health and substance use unified disorders within а framework. emphasizing coordination between mental health and substance abuse treatment professionals to provide holistic care [26].

Medication-Assisted Treatment (MAT) involves the use of medications, often in combination with counseling and behavioral therapies, to address substance use disorders. For individuals with cooccurring mental health issues. MAT can be tailored to target both aspects, improving overall treatment outcomes [23]. Cognitive-Behavioral Therapy (CBT), an evidence-based therapeutic approach, targets the cognitive and behavioral patterns associated with both mental health and substance use disorders. It helps individuals identify and change negative thought patterns and behaviors, promoting healthier coping mechanisms [27]. Motivational Interviewing (MI), client-centered approach, а focuses on enhancing intrinsic motivation for change, addressing ambivalence toward treatment and fosterina а commitment to behavioral modifications, making it valuable for individuals with dual diagnoses [28].

Dialectical Behavior Therapy (DBT) combines cognitive-behavioral techniques with mindfulness

strategies, beneficial for individuals with codisorders. addressing occurrina emotional dysregulation, self-destructive behaviors, and interpersonal difficulties common in this population [29]. Peer Support and 12-Step Programs, such as Alcoholics Anonymous (AA) or Narcotics Anonymous (NA), provide a supportive community for individuals struggling with both mental health and substance use disorders. Shared experiences and mutual support contribute to recovery [30].

Additionally, Recovery-Oriented Systems of Care (ROSC) emphasize a person-centered and recovery-focused approach, involving collaboration between various service providers to offer a continuum of care. ROSC addresses both mental health and substance use needs across the individual's recovery journey [31]. This comprehensive and interconnected approach ensures that individuals receive tailored and effective treatment, considering the intertwined nature of mental health and substance use disorders [32,33].

7. CONCLUSION

In summary, the interconnection between mental health and drug abuse is profound and the bidirectional, shaping well-being of individuals on emotional, psychological, and social levels. Mental health, vital for coping with stress and decision-making, faces a global challenge marked by conditions like depression and anxiety. Simultaneously, drug abuse, a pervasive global issue involving legal and illegal adversely impacts substances, physical, psychological, and social aspects. The bidirectional relationship intensifies challenges and for individuals healthcare providers. contributing to the development or worsening of mental health disorders. The impact extends beyond individuals, affecting societal burdens such as healthcare costs and criminal justice involvement. Treatment approaches, including IDDT, MAT, CBT, MI, DBT, Peer Support, 12-Step Programs, and ROSC, offer a holistic framework addressing complex for the relationship.

8. FUTURE PROSPECTIVE AND RECOMMENDATION

The review identifies a research gap in terms of the limited exploration of specific interventions addressing the association between mental

health and drug abuse disorders. While various treatment approaches are discussed, there is a need for more in-depth research evaluating the effectiveness and outcomes of the integrated interventions like IDDT), MAT, CB, MI, DBT, and others. Further studies should focus on the comparative efficacy of these approaches, considering diverse populations and factors, to provide a more comprehensive understanding of their impact on mental health and substance outcomes. Additionally. abuse research investigating innovative strategies to address the persistent challenges of stigma, limited treatment accessibility, and the cyclical nature of addiction would contribute valuable insights to enhance the effectiveness of interventions in this complex domain.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Sun Y, Wu Y, Fan S, Zhang L, Lin Y, Feng C, Chang J. Comparison of mental health symptoms before and during the COVID-19 pandemic: Evidence from a systematic review and meta-analysis of 134 cohorts. BMJ. 2023;380:e074224. Available:https://doi.org/10.1136/bmj-2022-0742241
- Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. New England Journal of Medicine. 2020;383 (6):510–512. Available:https://doi.org/10.1056/NEJMp20 08017
- 3. Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian Journal of Psychiatry. 2020;52: 102066.

Available:https://doi.org/10.1016/j.ajp.2020 .102066

- World Health Organization. Mental health; 2022. Available:https://www.who.int/newsroom/fact-sheets/detail/mental-healthstrengthening-our-response
- 5. National Institute on Drug Abuse. Commonly abused drugs; 2018.

Available:https://nida.nih.gov/sites/default/f iles/commonly_abused_drugs.pdf

- Jones TM, Hill KG, Epstein M, Lee JO, Hawkins JD, Catalano RF. Understanding the interplay of individual and socialdevelopmental factors in the progression of substance use and mental health from childhood to adulthood. Development and Psychopathology. 2016;28(3):721–741.
- Lim D, Lee WK, Park H. Disability-adjusted life years (DALYs) for mental and substance use disorders in the korean burden of disease study 2012. Journal of Korean Medical Science. 2016;31(2):191– 199.
- Gittins R, Missen L, Maidment I. Misuse of medication in adult substance misuse services: A systematic review protocol. British Medical Journal. 2021;11(6):1–6.
- Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. The New England Journal of Medicine. 2016;37 4(4):363–371.
- 10. Volkow ND, McLellan AT. Opioid abuse in chronic pain--misconceptions and mitigation strategies. The New England Journal of Medicine. 2016;374(13):1253–1263.
- 11. Magura S, Rosenblum A, Fong C. Factors associated with medication adherence among psychiatric outpatients at substance abuse risk. The Open Addiction Journal. 2011;4(1):58–64.
- 12. Volkow ND. Personalizing the treatment of substance use disorders. The American Journal of Psychiatry. 2020;177(2):113–116.
- Nestler EJ. Reflections on: A general role for adaptations in G-Proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Research. 2015; 1628(1):142–145.
- Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry. 2016;3(8):760– 773.
- 15. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. The Lancet Psychiatry. 2016;3(2):171– 178.
- 16. Corrigan PW. (Ed.). On the stigma of mental illness: Practical strategies for research and social change. American Psychological Association; 2005.

- Barrett EL, Teesson M, Mills KL. Associations between substance use, post-traumatic stress disorder and the perpetration of violence: A longitudinal investigation. Addictive Behaviors. 2014;39 (1):1075–1080.
- Longman-Mills S, Abel W, De La Haye W. Substance abuse during adulthood subsequent to the experience of physical abuse and psychological distress during childhood. West Indian Medical Journal. 2015;2(1):7–10.
- Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, Jayne M, Ma Y, Wong C. Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. 2006;26(24): 65 83–6588.
- 20. Sulzer D. Sonders MS. Poulsen NW. Galli Α. Mechanisms of neurotransmitter release by amphetamines: A review. Progress in Neurobiology. 2005;75(6):406-433.
- Sieghart W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Advances in Pharmacology. 2015;72 (1):53–96.
- 22. National Institute on Drug Abuse. Commonly Used Drugs Charts; 2020. Available:https://nida.nih.gov/researchtopics/commonly-used-drugs-charts
- 23. Substance Abuse and Mental Health Services Administration. Mental Health and Substance Use Disorders; 2018. Available:https://www.samhsa.gov/findhelp/disorders
- National Institute on Alcohol Abuse and Alcoholism. Alcohol's effects on the body; 2021. Available:https://www.niaaa.nih.gov/public ations/brochures-and-fact-sheets/alcoholseffects-body
 National Institute on Drug Abuse. What is
- National Institute on Drug Abuse. What is marijuana?; 2019. Available:https://nida.nih.gov/publications/ drugfacts/cannabis-marijuana
- Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin. 1998;24 (4):589–608.
- 27. McGovern MP, Lambert-Harris C, Acquilano S, Xie H, Alterman AI, Weiss RD. Cognitive behavioral

therapy for co-occurring substance use and posttraumatic stress disorders. Addictive Behaviors. 2009;34(10):892–8 97.

- Miller WR, Rollnick S. Motivational interviewing: Helping people change. Alcohol and Alcoholism. 2013;48 (3):376–377.
- Linehan MM. Skills Training manual for treating borderline personality disorder; 1993. Available:https://books.google.com.ng/boo ks/about/Skills_Training_Manual_for_Treat ing_Bord.html?id=qyZ0QgAACAAJ&redir_ esc=y
- Humphreys K. Professional interventions that facilitate 12-step self-help group involvement. Alcohol Research & Health: The Journal of the National Institute on

Alcohol Abuse and Alcoholism. 1999;23 (2):93–98.

- 31. Substance Abuse and Mental Health Services Administration. Recovery and Recovery Support; 2012. Available:https://www.samhsa.gov/findhelp/recovery
- 32. Keyes CL. Promoting and protecting mental health as flourishing: A complementary strategy for improving national mental health. The American Psychologist. 2007;62(2):95–108.
- Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62(6):617– 627.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/116110